Effect of CD34⁺ Total/Myeloid CD34⁺ Cell Progenitors and B-Lymphoid Progenitors Within the Bone Marrow Grafts on the Hematopoietic Recovery After Hematopoietic Stem Cell Transplantation.


DALVA K., Haskologlu S., DALVA AYDEMİR S., ÖZ M. D., ÖZTÜRK BİRGE A., Ipek S., ...Daha Fazla

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, cilt.20, sa.10, ss.937-944, 2022 (SCI-Expanded) identifier identifier identifier

Özet

© Başkent University 2022 Printed in Turkey. All Rights Reserved.Objectives: The influence of CD34+ cells on transplant outcomes following hematopoietic stem cell transplantation remains controversial. A minimum of 2.0 to 2.5 million CD34+ cells/kg of patient weight is requested for a rapid and durable engraftment. The aim of this study was to detect the ratio of CD34+ B-lymphoid progenitors (hematogones) in bone marrow grafts and investigate their effects on hematopoietic recovery after transplant. Materials and Methods: Our study included 41 patients who received a bone marrow graft from their HLA-matched donor from 2016 through 2019. The CD34+ cell numbers within the graft were detected using Stem-Kit (Beckman Coulter). The ratio of CD34+ hematogones was determined either by their light scatter characteristics or by the detection of CD34, CD19, or CD10 coexpressing cells in a separate tube. Results: The median number of CD34+ cells was 5.9 × 106/kg (0.8-14.3 × 106/kg). The CD34+ cells consisted of 71% (range, 35.7%-100%) and 29% (range, 5.7%-64.3%) myeloid and B-lymphoid progenitors, respectively. Percentage of CD34+ (P < .001) and total (P < .001) hematogones in correlation with donor age. Time of neutrophil engraftment was significantly longer (P = .039) when total infused CD34+ cell content was <3 × 106/kg. Conclusions: A remarkable population of hematogones within the CD34+ cell pool was detected in bone marrow grafts. Detection of the ratio of hematogones and most primitive stem cells (CD34+CD90+CD38-) may overall provide more information to build a better correlation between CD34+ cell content and the recovery of bone marrow.